Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00120679 | Treatment for Patients With Non-Small Cell Lung Cancer Who Developed Anemia Due to Chemotherapy | PHASE2 | COMPLETED | - | — | — | Oct 1, 2002 | Dec 1, 2003 | Dec 24, 2007 | - | — |
| Name | Type | Description |
|---|---|---|
| darbepoetin alfa | DRUG | - |
| recombinant human erythropoietin (rHuEPO) | DRUG | - |
Inclusion Criteria: - Subjects receiving multi-cycle chemotherapy for non-small cell lung cancer - Anemia due to chemotherapy (hgb less than or equal to 11.0 g/dL) - Expected to receive greater than or equal to 8 additional weeks of chemotherapy as part of their planned treatment - Karnofsky Perform...